gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 16 Apr 2015.

V-raf murine sarcoma viral oncogene homolog B1

This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located on chromosome X, has been identified for this gene. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: KRAS, CAN, Raf, HAD, EGFR
Papers using BRAF antibodies
Induction of autophagy and inhibition of melanoma growth in vitro and in vivo by hyperactivation of oncogenic BRAF
Pal Soumitro, In PLoS ONE, 2009
... All primary antibodies were purchased from Cell Signaling Technology except the following: anti-BRAF from Santa Cruz Biotechnology, anti-CRAF from BD Biosciences, ...
RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults
LiVolsi Virginia A et al., In CytoJournal, 2000
... The amplified products were electrophoresed on a 1.2% gel at 110 V for 1.5 hours and the BRAF bands (~220 bp) were cut using sterile blade and purified using Qiagen Gel Extraction Kit (Hilden, ...
A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)
Brinker Achim et al., In Current Chemical Genomics, 1993
... Unconjugated B-Raf antibody was from Santa Cruz Biotechnology (sc-5284), pMEK1/2 antibody from ...
Papers on BRAF
Multifunctional bioscaffolds for 3D culture of melanoma cells reveal increased MMP activity and migration with BRAF kinase inhibition.
Anseth et al., Boulder, United States. In Proc Natl Acad Sci U S A, 13 May 2015
UNASSIGNED: Matrix metalloproteinases (MMPs) are important for many different types of cancer-related processes, including metastasis.
Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling.
Sahai et al., Kyoto, Japan. In Cancer Cell, 13 May 2015
Intravital imaging of BRAF-mutant melanoma cells containing an ERK/MAPK biosensor reveals how the tumor microenvironment affects response to BRAF inhibition by PLX4720.
Transposon mutagenesis identifies genetic drivers of Braf(V600E) melanoma.
Jenkins et al., Houston, United States. In Nat Genet, 13 May 2015
UNASSIGNED: Although nearly half of human melanomas harbor oncogenic BRAF(V600E) mutations, the genetic events that cooperate with these mutations to drive melanogenesis are still largely unknown.
FAK to the Rescue: Activated Stroma Promotes a "Safe Haven" for BRAF-Mutant Melanoma Cells by Inducing FAK Signaling.
Serrels et al., Edinburgh, United Kingdom. In Cancer Cell, 13 May 2015
In this issue of Cancer Cell, Hirata and colleagues show that melanoma-associated fibroblasts can drive resistance to the BRAF inhibitor PLX4720 by stimulating matrix production/remodeling, and, consequently, survival signaling in melanoma cells via β1-integrin, Src, and FAK.
Validation of the Ion Torrent PGM Sequencing for the prospective routine molecular diagnostic of colorectal cancer.
Giannini et al., Roma, Italy. In Clin Biochem, 11 May 2015
In colorectal cancer (CRC), the molecular characterization of RAS and BRAF mutation status for prognostic and predictive purposes is commonly performed by different validated methods.
Erdheim-Chester disease.
Dagna et al., Milano, Italy. In Eur J Intern Med, 10 May 2015
Recent studies have demonstrated that ECD patients bare mutations in the proto-oncogene BRAF (and more rarely in other genes involved in the MAPK activation pathway), suggesting a critical role of this pathway in the pathogenesis and a possible clonal origin of the disease.
The BRAF Pseudogene Functions as a Competitive Endogenous RNA and Induces Lymphoma In Vivo.
Pandolfi et al., Boston, United States. In Cell, 09 May 2015
Here, we report that mice engineered to overexpress either the full-length murine B-Raf pseudogene Braf-rs1 or its pseudo "CDS" or "3' UTR" develop an aggressive malignancy resembling human diffuse large B cell lymphoma.
Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.
Goto et al., Tokyo, Japan. In Transl Lung Cancer Res, 30 Apr 2015
Fusions of the RET and ROS1 protein tyrosine kinase oncogenes with several partner genes were recently identified as new targetable genetic aberrations in cases of non-small cell lung cancer (NSCLC) lacking activating EGFR, KRAS, ALK, BRAF, or HER2 oncogene aberrations.
BRAF mutations in non-small cell lung cancer.
Cooper et al., Sydney, Australia. In Transl Lung Cancer Res, 30 Apr 2015
BACKGROUND: BRAF is a proto-oncogene encoding a serine/threonine protein kinase which promotes cell proliferation and survival.
The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer.
Cooper et al., Australia. In Transl Lung Cancer Res, 30 Apr 2015
Specimens were tested for mutations including EGFR, KRAS, and BRAF, using a multiplex PCR assay (OncoCarta Panel v1.0) and analyzed on the Agena Bioscience MassARRAY platform.
Beyond EGFR and ALK inhibition: Unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.
Mountzios et al., Manchester, United Kingdom. In Cancer Treat Rev, 28 Apr 2015
Nevertheless, in the recent years a number of other oncogenic drivers beyond EGFR and ALK inhibition have emerged as novel molecular targets with potential therapeutic implications, including mutations in the genes KRAS, BRAF, HER2, PI3KCA and DDR2, as well as ROS1 and RET rearrangements and MET, HER2 and FGFR1 gene amplifications.
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
McDermott et al., Boston, United States. In Clin Ther, 27 Apr 2015
Nivolumab has been associated with improved overall survival compared with dacarbazine in patients with previously untreated wild-type serine/threonine-protein kinase B-raf proto-oncogene BRAF melanoma.
Identification of new biomarkers for human papillary thyroid carcinoma employing NanoString analysis.
Dibner et al., Genève, Switzerland. In Oncotarget, 26 Apr 2015
In combination with BRAF mutation analysis, this predictive score closely correlated with the clinicopathological characteristics of the analyzed thyroid nodules.
Therapy-induced tumour secretomes promote resistance and tumour progression.
Massagué et al., New York City, United States. In Nature, 25 Apr 2015
Here we show that targeted therapy with BRAF, ALK or EGFR kinase inhibitors induces a complex network of secreted signals in drug-stressed human and mouse melanoma and human lung adenocarcinoma cells.
BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors.
Rosell et al., Madrid, Spain. In Transl Lung Cancer Res, 2013
In melanoma, the most commonly mutated gene is BRAF, with mutations usually occurring in about 50% of all tumours.
The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.
Pritchard et al., Leicester, United Kingdom. In Genes Dev, 2012
endogenous expression of (L597V)Braf leads to approximately twofold elevated Braf kinase activity and weak activation of the Mek/Erk pathway
BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper.
Eberhart et al., Baltimore, United States. In J Neuropathol Exp Neurol, 2012
The results of this study supported an important role for BRAF duplication and MAPK pathway activation in gliomas of the optic nerve proper.
BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.
Xing et al., Baltimore, United States. In Medicine (baltimore), 2012
Thus, in this meta-analysis, the BRAF mutation in PTC was significantly associated with PTC recurrence, lymph node metastasis, extrathyroidal extension, and advanced stage AJCC III/IV.
KRAS and BRAF mutations in Serbian patients with colorectal cancer.
Jankovic et al., Belgrade, Serbia. In J Buon, 2012
the spectrum and frequency distribution of the identified KRAS and BRAF mutations in Serbian patient with colorectal cancer are in good accordance with literature data.
A cardio-facio-cutaneous syndrome case with tight Achilles tendons.
Ozkinay et al., İzmir, Turkey. In Genet Couns, 2011
Cardio-facio-cutaneous syndrome is caused by heterogeneous mutations in BRAF gene.
share on facebooktweetadd +1mail to friends